A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients

Pancreatic cancer is one of the most aggressive cancers with a median survival time (MST) of

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncology reports 2013-09, Vol.30 (3), p.1094-1100
Hauptverfasser:	YUTANI, SHIGERU, KOMATSU, NOBUKAZU, YOSHITOMI, MUNEHIRO, MATSUEDA, SATOKO, YONEMOTO, KOJI, MINE, TAKASHI, NOGUCHI, MASANORI, ISHIHARA, YUKI, YAMADA, AKIRA, ITOH, KYOGO, SASADA, TETSURO
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Vaccines - therapeutic use Chemotherapy chemotherapy-resistant pancreatic cancer Cisplatin - administration & dosage Clinical trials Combined Modality Therapy Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Drug Combinations Drug Resistance, Neoplasm - immunology Female Follow-Up Studies Good Manufacturing Practice HLA Antigens - immunology Humans IgG response Immunoglobulins - analysis Laboratories Male Medical prognosis Middle Aged Multivariate analysis Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Neoplasm Staging NMR Nuclear magnetic resonance overall survival Oxonic Acid - administration & dosage Pancreatic cancer Pancreatic Neoplasms - immunology Pancreatic Neoplasms - mortality Pancreatic Neoplasms - therapy Peptide Fragments - immunology Peptide Fragments - therapeutic use Peptides personalized peptide vaccine Precision Medicine Prognosis Survival Rate Tegafur - administration & dosage Vaccination Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Pancreatic cancer is one of the most aggressive cancers with a median survival time (MST) of
ISSN:	1021-335X 1791-2431
DOI:	10.3892/or.2013.2556